ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 21 of 32 for:    "Pneumonia, Pneumococcal"

Understanding Pneumococcal Carriage and Disease 2017/2018

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03102840
Recruitment Status : Recruiting
First Posted : April 6, 2017
Last Update Posted : April 13, 2018
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
University of Oxford

Brief Summary:

Streptococcus pneumoniae is a type of bacteria that is carried (lives) in the nose of most individuals and can sometimes go on to cause severe infections such as meningitis and pneumonia. There are over 100 types of pneumococcus, and children in the UK have been routinely immunized against pneumococcal disease since 2006. A vaccine against 13 types of pneumococcus (PCV 13) was introduced into the UK in 2010, replacing a previous version that prevented 7 types.

Pneumococcal carriage in the Thames Valley region has been studied over the last 7 years with carriage rates having been shown to be reflective of potential severe pneumococcal disease and hence vaccine effect.

The main purpose of this study is to see whether the pneumococcal immunization program has changed the frequency and nature of pneumococcal bacteria carried by children, as this may give a clue as to what changes in pneumococcal disease are likely to be seen in the future. In addition, this study is especially timely given the possibility of a change in the PCV 13 immunization schedule that is currently being assessed in the 'Sched3' Immunization study (NCT02482636). Obtaining accurate baseline data will be important in informing the interpretation of any subsequent data on carriage rates obtained following introduction of the new schedule.

This study will enroll approximately 1600 children aged 13 to 48 months living in the Thames Valley and South Midlands and which have had three doses of 13-valent pneumococcal conjugate vaccine. The study consists of one visit done at a convenient venue (GP surgeries, educational/ play settings, or home) where a single nasal swab and an optional finger-prick blood sample for a sub-set of 632 participants, will be performed. No additional follow-up is needed. The study recruitment period will be done over 12 months.


Condition or disease Intervention/treatment
Streptococcus Pneumoniae Infection Streptococcus Pneumoniae, Invasive Disease Streptococcal Pneumonia Diagnostic Test: Nasopharyngeal swab Diagnostic Test: blood sampling

Detailed Description:

This is a cross sectional observational study to determine the point prevalence of pneumococcal carriage in children. In this study approximately 1600, healthy children aged 13-48 months who have received a complete course of PCV13 at least one month prior to study enrollment, will be recruited.

The study will be carried out in the Thames Valley and South Midlands. Parents/legal guardians will be approached either by website based advertisements, social media, poster advertisements and emailing and/or handing out information booklets through their child's nurseries, GP Surgeries and educational/play settings. The investigators may also identify potential participants by mailing out invitation letters and leaflets to age appropriate children via the Open Exeter system of National Health Application and Infrastructure Services, the Child Health Computer Department, equivalent NHS database or through the Clinical Research Network. Parents/legal guardians of potential participants who have expressed interest will be directed to the Oxford Vaccine group (OVG) website where they will be able to access the participant information booklet and if appropriate complete online self-screening. If parents approach OVG to express interest, the information booklet will be sent to them and they may be telephone screened.

This study will involve a one off visit. The study visit will be arranged to occur in a convenient venues such as: hospital out patients, university clinic rooms, village halls, church halls, nurseries, participant's homes, sporting and recreational areas, GP practices and other similar venues where pre-school children frequently attend. Permission would be seek from the above venues to carry out any study procedures on their premises. Pre-arranged dates and times will be offered to parents/legal guardians by online booking, phone call or email.

During the visit the investigators would go through the details of the study and provide an opportunity for further questions. For those willing to proceed the investigators would then ask participants to sign a consent form and collect demographic information. A nasopharyngeal swab will be taken, and if consented to do so an optional blood sample will be performed in a subset of 632 participants. No further visits or follow-up will be required.


Study Type : Observational
Estimated Enrollment : 1600 participants
Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Cross-sectional Study to Establish the Point Prevalence of Serotype 19A Pneumococcal Nasopharyngeal Carriage of Fully Vaccinated Children Aged 13-48 Months 7 Years Following Introduction of PCV-13
Actual Study Start Date : June 26, 2017
Estimated Primary Completion Date : May 17, 2018
Estimated Study Completion Date : December 31, 2018

Group/Cohort Intervention/treatment
Children nasal swab only
Pneumococcal nasopharyngeal carriage in children aged 13-48 months who have previously received PCV13
Diagnostic Test: Nasopharyngeal swab
Nasopharyngeal swab will be performed in all participants

Children nasal swab + serum
Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 13-48 months who have previously received PCV13
Diagnostic Test: Nasopharyngeal swab
Nasopharyngeal swab will be performed in all participants

Diagnostic Test: blood sampling
Blood sampling will be done by finger-prick in a sub-set of participants




Primary Outcome Measures :
  1. Serotype 19A-specific carriage rate in healthy children aged 13 to 48 months in 2017/2018. [ Time Frame: 2 year ]
    To determine the serotype 19A-specific carriage rate in healthy children aged 13 to 48 months in 2017/2018, seven years following introduction of PCV13 and to compare this to carriage rates observed in 2014/2015 (OVG 2013/05 study).


Secondary Outcome Measures :
  1. To determine the PCV13 vaccine-type pneumococcal serotype-specific nasopharyngeal (NP) carriage rate and serotype distribution in children aged 13 to 48 months who have received a full course of PCV13 [ Time Frame: 2 year ]
    Presence of PCV13 vaccine type pneumococcal serotypes NP swab samples by microarray analysis

  2. To determine the non-PCV vaccine type pneumococcal serotype-specific NP carriage rate and serotype distribution in children aged 13 to 48 months who have received a full course of PCV13 [ Time Frame: 2 years ]
    Presence of PCV13 non-vaccine type pneumococcal serotypes on NP swab samples by microarray analysis

  3. To determine PCV-13 serotype specific anti-pneumococcus antibody concentrations in fully immunised 13 to 48 month old children [ Time Frame: 2 years ]
    Antibody concentration by ELISA (finger-prick blood sample) for PCV13 vaccine-types


Other Outcome Measures:
  1. To compare PCV-13 serotype specific anti-pneumococcal antibody concentrations in age matched, fully immunized 13 to 48 month old children to historical cohorts from the OVG 2013/05 study. [ Time Frame: 2 years ]
    Antibody concentration by ELISA (finger-prick blood sample) for PCV13 vaccine-types obtained in current study and biobank samples of historical cohorts

  2. To assess for carriage of multiple pneumococcal strains in participants in the current study and on stored samples from OVG 2013/05 study. [ Time Frame: 2 years ]
    Microarray analysis of culture 'sweeps' obtained in the current and OVG 2013/05 studies


Biospecimen Retention:   Samples Without DNA
Bacteria grown from nasopharyngeal swabs Serum to measure serotype specific antibodies levels


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   13 Months to 48 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
1600 children aged 13 to 48 months, who have received 3 doses of PCV13
Criteria

Inclusion Criteria:

  1. Parent/guardian of participant is willing and able to give informed consent for participation in the study.
  2. In good health as determined by a brief medical history and/or clinical judgement of the investigator.
  3. Have received three doses of PCV13 as per infant immunization schedule (as confirmed by red book or through vaccination history and age). Vaccination history is confirmed by the child's GP or CHCD. The visit and sampling may still proceed if the vaccination history has not been confirmed beforehand and the participant can be subsequently excluded if they were found to not have received all three doses of PCV13.
  4. Aged 13-48 months and at least 28 days since their third PCV13 vaccination.
  5. Able (in the Investigators opinion) and willing to comply with all study requirements.

Exclusion Criteria:

  1. Parent/legal guardian unwilling or unable to give written informed consent to participate in the study.
  2. Parent/legal guardian less than 18 years of age at time of enrollment.
  3. Parent/legal guardian is listed on the study delegation log.
  4. Children who were known to be un-immunized or have an incomplete course of PCV13.
  5. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  6. History of bleeding disorder.

Temporary exclusion criteria:

  1. Febrile illness or temperature of 38°C or above on the day of the visit or in the preceding 24 hours.
  2. Respiratory illness on the day of the study visit or in the preceding 24 hours. A respiratory illness will be classified as a combination of at least two of the following symptoms: cough, sore throat, and runny nose.
  3. Administration of antibiotics in the month prior to sampling.
  4. History of an acute nose bleed (within the last 24 hours), or recent (within the last 3 months) nasal/craniofacial surgery.
  5. Receipt of blood products and/or plasma derivatives or any parenteral immunoglobulin preparation within 90 days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03102840


Contacts
Contact: Matthew Snape, MD 01865611400 matthew.snape@paediatrics.ox.ac.uk
Contact: Rachel Craik 01865611400 rachel.craik@paediatrics.ox.ac.uk

Locations
United Kingdom
Centre for Clinical Vaccinology and Tropical Medicine Recruiting
Oxford, Oxfordshire, United Kingdom, OX3 7LE
Contact: Rachel Craik    01865 611400    info@ovg.ox.ac.uk   
Sponsors and Collaborators
University of Oxford
Pfizer

Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT03102840     History of Changes
Other Study ID Numbers: OVG 2017/03
First Posted: April 6, 2017    Key Record Dates
Last Update Posted: April 13, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Oxford:
Carriage
Immunogenicity
Pneumococcal conjugate vaccine 13 (PCV 13)
Children
Pneumococcus

Additional relevant MeSH terms:
Pneumonia
Pneumococcal Infections
Pneumonia, Pneumococcal
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Streptococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Pneumonia, Bacterial